Evidence map›Paper›PMID 32764941›Full record

ArticleInternational journal of nanomedicine2020

Efficient miRNA Inhibitor with GO-PEI Nanosheets for Osteosarcoma Suppression by Targeting PTEN.

Lingling Ou, Haiyingjie Lin, Yuwei Song, Guoqiang Tan, Xiujuan Gui, Jinyuan Li, Xiaoting Chen, Zhendong Deng, Shaoqiang Lin

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lingling OuDepartment of Stomatology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, People's Republic of China.
Haiyingjie LinDepartment of Orthopedics, The Third Affiliated Hospital, Southern Medical University, Guangzhou 510630, People's Republic of China.
Yuwei SongDepartment of Stomatology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, People's Republic of China.
Guoqiang TanDepartment of Stomatology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, People's Republic of China.
Xiujuan GuiDepartment of Stomatology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, People's Republic of China.
Jinyuan LiDepartment of Stomatology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, People's Republic of China.
Xiaoting ChenIntegrated Traditional and Western Medicine Research Center of the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510000, People's Republic of China.
Zhendong DengIntegrated Traditional and Western Medicine Research Center of the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510000, People's Republic of China.
Shaoqiang LinDepartment of Stomatology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, People's Republic of China.
First Affiliated Hospital of Jinan University · CNFirst Affiliated Hospital of Guangdong Pharmaceutical University · CNThird Affiliated Hospital of Southern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGene therapy is considered a novel way to treat osteosarcoma, and microRNAs are potential therapeutic targets for osteosarcoma. miR-214 has been found to promote osteosarcoma aggression and metastasis. Graphene oxide (GO) is widely used for gene delivery for the distinct physiochemical properties and minimal cytotoxicity.

methodsPolyethyleneimine (PEI)-functionalized GO complex was well-prepared and loaded with miR-214 inhibitor at different concentrations. The load efficacy was tested by gel retardation assay and the cy3-labeled fluorescence of cellular uptake. The experiments of wound healing, immunofluorescence staining, Western blot, qRT-PCR and immunohistochemical staining were performed to measure the inhibitory effect of the miR-214 inhibitor systematically released from the complexes against MG63, U2OS cells and xenograft tumors.

resultsThe systematic mechanistic elucidation of the efficient delivery of the miR-214 inhibitor by GO-PEI indicated that the inhibition of cellular miR-214 caused a decrease in osteosarcoma cell invasion and migration and an increase in apoptosis by targeting phosphatase and tensin homolog (PTEN). The synergistic combination of the GO-PEI-miR-214 inhibitor and CDDP chemotherapy showed significant cell death. In a xenograft mouse model, the GO-PEI-miR-214 inhibitor significantly inhibited tumor volume growth.

conclusionThis study indicates the potential of functionalized GO-PEI as a vehicle for miRNA inhibitor delivery to treat osteosarcoma with low toxicity and miR-214 can be a good target for osteosarcoma therapy.

Indexed as

Molecular Targeted TherapyAnimalsApoptosisBone NeoplasmsCell DeathCell Line, TumorCell MovementCell ProliferationCombined Modality TherapyGraphiteHumansMiceMicroRNAsOsteosarcomaPolyethyleneiminePTEN Phosphohydrolasegraphene oxideGraphiteMicroRNAsMIRN214 microRNA, humanPolyethyleneiminePTEN PhosphohydrolasePTEN protein, humanGO-PEI-miR-214 inhibitorosteosarcomatumor suppression

Identifiers

PMID32764941
PMCPMC7372002
OpenAlexW3042594421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.